TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01645033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerized Cognitive Behavioral Therapy (CBT)
Description: Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~* Teaching about the treatment program~* Teaching important ideas about sexual behaviors risks~* Increasing knowledge about specific sexually transmitted diseases~* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~* Teaching about the treatment program~* Teaching important ideas about sexual behaviors risks~* Increasing knowledge about specific sexually transmitted diseases~* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]
Study: NCT04308083

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant placement
Description: Implants will be placed according to the manufacturer recommendations. Implants will be placed at 1.5 to 2.0 mm from the adjacent natural tooth. However, these distances will be directed by the prosthetic crown needed and they will be recorded in the CRF.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: dental implant placement
Description: Implants will be placed according to the manufacturer recommendations. Implants will be placed at 1.5 to 2.0 mm from the adjacent natural tooth. However, these distances will be directed by the prosthetic crown needed and they will be recorded in the CRF.
Study: NCT03766113

Intervention type: OTHER
Group type: OTHER
Intervention: Neurofeedback coupling electroencephalogram and functional MRI in time actual or a neurofeedback-free mental imaging program with electroencephalogram recording
Description: Interventional group (5 weeks) : 5 sessions of neurofeedback coupling electroencephalogram and functional MRI in time actual and 9 sessions of electroencephalogram-neurofeedback program~Controle Group (5 weeks) : 14 sessions of neurofeedback-free mental imaging program
Study: NCT02913833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain evaluation
Description: Pain will be assessed four times per day on a visual analogic scale.
Study: NCT04534049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Strength Training (IST)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Endurance Training (SET)
Study: NCT00296049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Study: NCT02378077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat biopsy during scheduled abdominal surgery
Description: Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Aspiration
Description: Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Aspiration
Description: Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil Supplement
Description: Fish Oil supplementation for three months.
Study: NCT01204905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir and Maraviroc in combination
Description: Raltegravir 400 mg tablet twice a day, \~12 hours (10 to 14 hours) apart~Maraviroc 300 mg tablet twice a day, \~12 hours (10 to 14 hours) apart
Study: NCT00268944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme
Description: 20 mg/kg qow
Study: NCT00100568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/zidovudine
Description: 150mg lamivudine/300mg zidovudine tablet taken orally twice daily
Study: NCT04196855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Terrosa 20 micrograms/80 microliters solution for injection. Each dose of 80 microliters contains 20 micrograms of teriparatide.~One cartridge of 2.4 mL of solution contains 600 micrograms of teriparatide (corresponding to 250 micrograms per mL).~Teriparatide, rhPTH(1-34), produced in E. coli, using recombinant DNA technology, is identical to the 34-N-terminal amino acid sequence of endogenous human parathyroid hormone.
Study: NCT00824252

Intervention type: BEHAVIORAL
Intervention: Questionnaires & Study Visit
Description: Individual Questionnaires (1 hour) and videotaped discussion during Study Visit (1 1/4 hours)
Study: NCT01715688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alkalinized lidocaine
Description: Administration of alkalinized lidocaine in the endotracheal tube cuff

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Administration of saline in the endotracheal tube cuff
Study: NCT02314156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone Acetate
Description: Given transdermally
Study: NCT03064451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cartofinder guided ablation followed by PVI
Description: cartofinder guided ablation followed by PVI
Study: NCT03149198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mat Pilates exercises
Description: The exercise program based on the pilates method will be performed on the ground in the group room of the FACISA / UFRN Physiotherapy School Clinic in Santa Cruz. The room has ample space and air conditioning for better patient accommodation. The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by a physical therapy student along with the research coordinator. A total of 10 exercises will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic aerobic exercises
Description: The aerobic exercise program will be held in the therapeutic pool of the Physiotherapy School Clinic of FACISA / UFRN in Santa Cruz. The pool is heated and provides better effects to the proposed treatment.~The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by another physical therapy student along with the research coordinator.
Study: NCT02305056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C13 N15 Valine
Description: C13 N15 Valine administration
Study: NCT04534049

Intervention type: OTHER
Group type: OTHER
Intervention: Flexibility Training (FT)
Study: NCT04446767

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: polarized light
Description: bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks
Study: NCT00016016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study: NCT04446767

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Care
Description: Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
Study: NCT00844415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: 2.14 mg/kg BID to a max 150 mg BID
Study: NCT03580525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine saline infusion 0.00mcg/kg/s
Description: saline 0.00mcg/kg/s

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine infusion 0.24mcg/kg/s
Description: nicotine 0.24mcg/kg/s

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine infusion 0.096mcg/kg/s
Description: nicotine 0.096mcg/kg/s

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine infusion 0.048 mcg/kg/s
Description: nicotine 0.048mcg/kg/s

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine infusion 0.024mcg/kg/s
Description: nicotine 0.024mcg/kg/s
Study: NCT00016016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory procedure
Description: Correlative studies
Study: NCT00003170

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glutamine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03713151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dividat FIT
Description: The study intervention is a blended therapy approach of face-to-face physiotherapy sessions with an interactive tablet-based home exercise program.
Study: NCT02003768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 80 patients are randomly allocated into two groups: In TIVA group, propofol based total intravenous anesthesia is used to induce and maintain anesthesia for laparoscopic cholescystectomy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: 80 patients are randomly allocated into two groups : In Des group, inhalation anesthesia using desflurane is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
Study: NCT02597972

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fracture repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fracture repair with joint replacement
Study: NCT03904004

Intervention type: PROCEDURE
Intervention: Peroral endoscopic myotomy
Description: Endoscopic myotomy after performing a tunnel to reach the muscular layer through a mucosal incision

Intervention type: PROCEDURE
Intervention: Neumatic dilatation
Description: Inflation of a ballon of specific diameter in the gastro-oesophageal junction

Intervention type: PROCEDURE
Intervention: Botulinum toxin injection
Description: Injection of botulinic toxin to inhibit the contraction of the gastro-oesophageal junction muscular layer

Intervention type: PROCEDURE
Intervention: Laparoscopic Heller Myotomy
Description: Five or six small incisions are made in the abdominal wall and laparoscopic instruments are inserted. The myotomy is a lengthwise cut along the oesophagus, starting above the lower oesophageal sphincter (LOS) and extending down onto the stomach a little way. The oesophagus is made of several layers, and the myotomy only cuts through the outside muscle layers which are squeezing it shut, leaving the inner mucosal layer intact.
Study: NCT00832689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan and Gemcitabine
Study: NCT04063397

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Serial echocardiograms will be done on all patients pre-delivery, and at 3-6 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Serial echocardiograms will be done on all patients pre-delivery, and at 3-6 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Serial blood draws at same time points as echocardiograms for biomarker levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Serial blood draws at same time points as echocardiograms for biomarker levels
Study: NCT00576147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrascanner
Description: The main Near-Infrared spectroscopy (NIRS) head measurement
Study: NCT04432168

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetoscopic Laser Surgery
Description: Fetoscopic Photocoagulation of the connecting vascular anastomoses on the surface of the placenta.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Treatment
Description: In the control group, the choices of treatment include expectant management, intrauterine transfusion (IUT) (with or without partial exchange transfusion (PET)) or preterm delivery, depending on the judgment of the fetal surgeon with regard to the gestational age and state of the disease.~* Expectant management will consist of close monitoring with ultrasound including Doppler measurements of the middle cerebral artery peak systolic velocity (MCA-PSV), at least every week.~* IUT: the intrauterine infusion of red blood cells into the circulation of the donor twin treat anemia.~* PET: the intrauterine infusion of saline into the circulation of the recipient twin to treat polycythemia.~* Preterm delivery: Induction of labor or cesarean section before 36 weeks of gestation.
Study: NCT06409507

Intervention type: GENETIC
Intervention: FKBP12 expression
Description: The expressions of FKBP12 were determined by immunohistochemistry (IHC) , and the immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels, and IRS (8-12) represented high expression levels.

Intervention type: GENETIC
Intervention: FKBP12 expression
Description: The expressions of FKBP12 were determined by immunohistochemistry (IHC) , and the immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels, and IRS (8-12) represented high expression levels.
Study: NCT04941976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% benzydamine hydrochloride spray oromucosal solution
Description: Single application of 0.3% benzydamine hydrochloride spray oromucosal solution. Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single 3 mg lozenge of benzydamine hydrochloride (mint flavour)
Description: Single 3 mg lozenge of benzydamine hydrochloride (mint flavour). Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution.
Study: NCT02159768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airtraq visualization
Description: Larynx visualization with Airtraq and attached handphone
Study: NCT00462267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enriched lifestyle intervention
Description: Multi-component lifestyle intervention
Study: NCT00994760

Intervention type: DRUG
Intervention: Instanyl (Intranasal Fentanyl)
Description: This was an observational study. Therefore, the physician decided about dosage according to individual needs.
Study: NCT02407691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care 101 plus mental health
Description: A facility-based stepped care intervention combining depression case detection by non-physician clinicians with group counselling intervention delivered by lay-health workers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Primary Care 101
Description: Standard Primary Care 101 guideline with standard training
Study: NCT02343952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.
Study: NCT03398824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin HCl
Description: Receive metformin HCl
Study: NCT02096471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Study: NCT05230290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KD6001 Injection
Description: Solution for intravenous injection
Study: NCT04864327

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief smoking cessation advise
Description: The tobacco cessation protocol consisted of performing a routine assessment (asking) of cigarette use; providing advice on the importance of quitting; performing an assessment of the tobacco user's readiness to quit; assisting in setting a quit date; and making arrangements for follow-up visits. This protocol is popularly known as the 5A's strategy (The first 3A's should be delivered to all smokers regardless of their willingness to quit). Tobacco users were identified by staff nurses. Clinicians provided brief advice on quitting, and the researcher assessed the patient's dependence and readiness to quit. Patients who were not ready to quit were motivated to consider quitting, whereas those who were ready to quit were referred to practitioners who could assist them and follow them in the tobacco cessation clinic
Study: NCT00720720

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plant sterol enriched margarine
Description: Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: plant sterol enriched margarine
Description: Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo margarine
Study: NCT03170492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RehaCom Computerized Cognitive Training for 480 minutes
Description: Student OT doctoral researchers will guide the subject when participating in the RehaCom program. RehaCom is computer hardware and software designed for assisted cognitive rehabilitation. The program is designed to target specific aspects of attention, concentration, memory, perception, and problem-solving. As the training goes on, the tasks will become easier or harder depending on the subject's performance. The first session will begin with a screening module with an example and a practice session to make sure the client understands the task. After screening, the results page shows the subject's performance compared with age-matched norms. This gives a helpful indication as to the severity of the deficit and advises the researcher on the particular training module to be used. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pencil-and-Paper Cognitive Training for 480 minutes
Description: Student OT doctoral researchers will engage the subject in various pen-and-paper exercises designed to improve cognitive functions: attention and concentration, memory, language, calculation, and orientation. These could include, but are not limited to: word puzzles, calculation or number puzzles, and map reading. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
Study: NCT05478967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVA injection before vitrectomy
Description: Patients in IVA group received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)
Study: NCT01660646

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral: community sensitization
Description: Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
Study: NCT06107790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS022
Description: 8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Bitartrate
Description: Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). 3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~Second section:9 treatment cycles, 3 weeks/cycle, 27 weeks. Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). The investigator may decide whether to continue treatment with vinorelbine at his discretion.~3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine Bitartrate
Description: Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). 3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~Second section:9 treatment cycles, 3 weeks/cycle, 27 weeks. Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). The investigator may decide whether to continue treatment with vinorelbine at his discretion.~3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.